Suppr超能文献

建立罕见病患者登记系统:理由与挑战。

Establishing Patient Registries for Rare Diseases: Rationale and Challenges.

机构信息

National Organization for Rare Disorders, 55 Kenosia Avenue, Danbury, CT, 06810, USA.

出版信息

Pharmaceut Med. 2020 Jun;34(3):185-190. doi: 10.1007/s40290-020-00332-1.

Abstract

Globally, an estimated 350 million people are affected by a rare disease diagnosis. Knowledge limitations persist for the majority of rare conditions due to systemic and structural challenges in healthcare and research. Disease-specific patient populations are often small and geographically dispersed; funding support for research is restricted; and diagnostic delays are common due to disease complexities, limited medical training for practitioners, and evolving foundational knowledge related to disease characterization. Patient registries can be effective, convenient, and cost-efficient tools to support documentation of the natural history of a disease, centering patients as research partners in the process while uniting rare communities around a common initiative. Current global trends towards innovative and patient-centered healthcare are enabling patient registries to increasingly emerge as valuable tools for use within rare disease research and drug development. This article describes the value of and rationale for establishing rare disease patient registries and the considerations and challenges that stakeholders, such as researchers, industry, health care providers, and patient community organizations, may encounter.

摘要

据估计,全球有 3.5 亿人受到罕见病诊断的影响。由于医疗保健和研究中的系统性和结构性挑战,大多数罕见疾病的知识仍然有限。特定疾病的患者人群通常规模较小且分布在地理上分散;由于疾病的复杂性、医生培训有限以及与疾病特征相关的基础知识不断发展,研究资金支持受到限制;诊断延迟也很常见。患者登记处可以是一种有效的、方便的、具有成本效益的工具,支持记录疾病的自然史,将患者作为研究合作伙伴纳入这一过程,同时将罕见疾病社区团结在一个共同的倡议下。目前,全球创新和以患者为中心的医疗保健趋势正在使患者登记处越来越多地成为罕见病研究和药物开发的有价值工具。本文描述了建立罕见病患者登记处的价值和基本原理,以及研究人员、行业、医疗保健提供者和患者社区组织等利益相关者可能遇到的考虑因素和挑战。

相似文献

5
Rare disease registries: a call to action.罕见病登记处:行动呼吁。
Intern Med J. 2017 Sep;47(9):1075-1079. doi: 10.1111/imj.13528.
6
Facilitating Clinical Studies in Rare Diseases.促进罕见病临床研究。
Adv Exp Med Biol. 2017;1031:125-140. doi: 10.1007/978-3-319-67144-4_6.

引用本文的文献

4

本文引用的文献

2
Implementation and relevance of FAIR data principles in biopharmaceutical R&D.在生物制药研发中实施和应用 FAIR 数据原则。
Drug Discov Today. 2019 Apr;24(4):933-938. doi: 10.1016/j.drudis.2019.01.008. Epub 2019 Jan 25.
6
The Challenge of Rare Diseases.罕见病的挑战。
Chest. 2018 Jun;153(6):1309-1314. doi: 10.1016/j.chest.2017.12.018. Epub 2018 Jan 8.
7
Data Quality in Rare Diseases Registries.罕见病登记处的数据质量。
Adv Exp Med Biol. 2017;1031:149-164. doi: 10.1007/978-3-319-67144-4_8.
9
Creating an effective clinical registry for rare diseases.为罕见病创建有效的临床注册中心。
United European Gastroenterol J. 2016 Jun;4(3):333-8. doi: 10.1177/2050640615618042. Epub 2015 Nov 13.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验